CTA
NVCR icon

Carillon Tower Advisers’s NovoCure NVCR Stock Holding History

Carillon Tower Advisers’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$53.8M Buy
310,642
+232,748
+299% +$31.9M 0.33% 100
2020
Q3 		$8.67M Buy
+77,894
New +$6.23M 0.12% 272
2020
Q2 		– Sell
-572,680
Closed -$36.9M – 474
2020
Q1 		$36.9M Hold
572,680
– – 0.36% 94
2019
Q4 		$48.3M Hold
572,680
– – 0.32% 102
2019
Q3 		$42.8M Buy
+572,680
New +$45.8M 0.3% 118

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Carillon Tower Advisers's NVCR Position: Q4 2020 in Review

Carillon Tower Advisers increased its NovoCure (NVCR) stake by 299% in Q4 2020, buying an estimated $31.9M and bringing the position to 310,642 shares worth $53.8M. The position accounts for 0.33% of the portfolio, ranked #100.

Carillon Tower Advisers first reported a position in NVCR in Q3 2019 and has held it in 5 quarters since. 356 funds tracked by Wall St. Rank hold NVCR as of Q4 2020.

  • Carillon Tower Advisers held 310,642 shares of NovoCure worth $53.8M as of Q4 2020.
  • Carillon Tower Advisers bought 232,748 NovoCure shares in Q4 2020, an estimated $31.9M.
  • NovoCure made up 0.33% of Carillon Tower Advisers's portfolio in Q4 2020, its #100 holding.
  • Carillon Tower Advisers first reported a position in NovoCure in Q3 2019 and has held it in 5 quarters since.
  • 356 funds tracked by Wall St. Rank held NovoCure as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.